Larazotide acetate
Revision as of 17:17, 3 February 2022 by User123 (talk | contribs) (Created page with "== Studies on larazotide acetate == * ''The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study'' https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2007.03413.x ** This 2007 paper for a small pilot study noted that larazotide improved intestinal permeability. "Following acute gluten exposure, a 70% increase in intestinal permeability was detected in the placebo...")
Studies on larazotide acetate
- The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2007.03413.x
- This 2007 paper for a small pilot study noted that larazotide improved intestinal permeability. "Following acute gluten exposure, a 70% increase in intestinal permeability was detected in the placebo group, while none was seen in the AT-1001 group."
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study https://doi.org/10.1111/apt.12147
- This 2012 paper noted that the study used the lactulose-to-mannitol (LAMA) ratio to measure intestinal permeability. "No significant differences in LAMA ratios were observed between larazotide acetate and placebo groups."
- A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge https://dx.doi.org/10.1038%2Fajg.2012.211
- This 2012 paper noted: "The increase in LAMA ratio associated with the gluten challenge was not statistically significantly greater than the increase in the gluten-free control."
- Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial https://dx.doi.org/10.1053%2Fj.gastro.2015.02.008
- This 2015 paper noted that "results were mixed".
MIS-C related studies:
- Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier https://doi.org/10.1172/JCI149633
- This 2021 paper argues: "These mechanistic data on MIS-C pathogenesis provide insight into targets for diagnosing, treating, and preventing MIS-C, which are urgently needed for this increasingly common severe COVID-19–related disease in children."